Notification of Half Year Results

RNS Number : 1365X

Alliance Pharma PLC

26 August 2020

 

26 August 2020

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Notification of Half Year Results,

Analyst Conference Call and Webcast

Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the six months ended 30 June 2020 on Tuesday 22 September 2020.

A conference call for analysts will be held at 10.30am on 22 September 2020; analysts who require dial-in details, please contact Buchanan at [e-mail] .

A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 22 September 2020 at this link:

https://webcasting.buchanan.uk.com/broadcast/5f3fbab0b14d87262643a98b

The recorded webcast will also be made available at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors/ .

For more information, please contact Buchanan on 020 7466 5000 or email [e-mail] .

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
[e-mail]
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Huw Jeremy
Corporate Broking: James Black

Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website :  www.alliancepharmaceuticals.com

 

END

 

 

NORSEAFMIESSESA